Hasil Pencarian - Nidal Al‐Huniti

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer

    Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer oleh Mario Nagase, Sergey Aksenov, Hong Yan, James Dunyak, Nidal Al‐Huniti

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

    Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia oleh Xia Pu, Mark Sale, Feng Yang, Yi Zhang, John D. Davis, Nidal Al‐Huniti

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

    Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities oleh Nidal Al‐Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer

    Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer oleh Jenny‐Hoa Nguyen, Daniel Epling, Nancy Dolphin, Anne Paccaly, Daniela Conrado, John D. Davis, Nidal Al‐Huniti

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach oleh Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

    A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab oleh Masood Khaksar Toroghi, Jim Bosley, Lyn M. Powell, Yi Zhang, Feng Yang, Xia Pu, John D. Davis, Nidal Al‐Huniti

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model

    Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model oleh Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski, Gabriel Helmlinger

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A drug‐disease model for predicting survival in an Ebola outbreak

    A drug‐disease model for predicting survival in an Ebola outbreak oleh Masood Khaksar Toroghi, Nidal Al‐Huniti, John D. Davis, A. Thomas DiCioccio, Ronda Rippley, Alina Baum, Christos A. Kyratsous, Sumathi Sivapalasingam, Joel Kantrowitz, Mohamed A. Kamal

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: